Rottendorf Pharma GmbH is participating in a research project dedicated to a photodynamic tumor therapy. The “Medi-WING” promotion program is supported by the German Ministry of Education and Research (BMBF). Photostabilizers are a new and promising category of substances designed to enhance local effectiveness. The ingested photostabilizers are specifically activated through laser light to destroy cancer cells while minimizing damage to healthy cells.
 
Stefanie Krenzlin of Rottendorf Pharma, together with six public and industrial partners, will investigate suitable active substances for a tumor therapy with the goal of developing innovative dosage forms. After the development phase, Rottendorf will continue to be responsible for the scale-up of the product.